For example, in a study of GBM patients treated with the pan-VEGFR inhibitor cediranib (AZD 2171), blood levels of the proangiogenic factors bFGF and SDF1α were noted to be higher in patients at the time of tumor progression or relapse as compared to the levels observed during the phase in which the patients showed a response to cediranib therapy [142]. This evidence concerns the gene FGF2 and neoplasm.